Turner Pope Investor Evening May 2019

Turner Pope Investor Evening May 2019

Deltex Medical Group PLC This medical technology company manufactures, markets and is a global leader in Oesophageal Doppler Monitoring systems. Their minimally invasive, real time, blood flow monitoring equipment is incredibly well positioned from both a patient safety and cost saving perspective; reducing post-operative complications, intensive care admissions and length of hospital stay. A extensively developed technology from a well established company benefitting patients and healthcare providers, addressing wide market requirement.https://youtu.be/Aohqjpp6TvI Integumen PLC Combine data analytics with access to therapeutic operational expertise, specialising in Skin. Their core offering, Labskin AI has attracted numerous blue chip household names in the pharmaceutical,…read more >
Turner Pope Investor Evening February 2019

Turner Pope Investor Evening February 2019

Our first Investor Evening of the New Year of 2019 was a great success held on Monday 11th February at The City’s 5* hotel, The Ned. The following companies attended who provided us with an update on the progress of their ongoing projects and plans for the New Year.   Anglo African Oil & Gas – David Sefton, Executive Chairman The company is focusing on developing its Congo based asset, Tilapia. On the back of successful drilling, the company is updating shareholders on hitting the targeted Djeno zone as well as addressing recent concerns over financing.   Bluerock Diamonds – Adam…read more >
Velocys plc fund raise of approximately £18.4 million

Velocys plc fund raise of approximately £18.4 million

Velocys plc (VLS.L), the renewable fuels company, is pleased to announce that it intends to raise approximately £18.4 million (gross) by way of a firm placing and placing and open offer. Highlights: Fund raising of approximately £18.4 million (before expenses): o  Approximately £14 million (before expenses) by way of a firm placing of 139,605,000 New Ordinary Shares (the “Firm Placing Shares”) at a placing price of 10 pence per share (the “Placing Price”) (the “Firm Placing”); and o  £4.4 million (before expenses) by way of an open offer (the “Open Offer”) made to Eligible Shareholders of 44,057,946 New Ordinary Shares (the “Open Offer Shares”)…read more >
Turner Pope Investor Evening December 2018

Turner Pope Investor Evening December 2018

TPI are bringing a special Christmas treat to you from the investor evening which was held on Monday 10th December at one of London’s prestige locations, The RAF Club, Mayfair. We had the privilege of hosting yet another of our successful Investor Evenings for the following companies to provide us with an update as to the progress of their ongoing projects.   Eurasia Mining PLC (EUA.L) – Keith Byrne, Resource and Exploration Geologist Platinum Group Metals & Gold exploration company focused on Russia. Recent news flow regarding the Monchetundra mining permit. Run up in the share price from 0.25p per share at…read more >
Turner Pope Investor Evening October 2018

Turner Pope Investor Evening October 2018

If Monday’s aren’t for you, then you need to get yourself down to one of our Investor Evenings. On Monday 1st October, we had the privilege of hosting yet another of our successful Investor Evenings for the following companies to provide us with an update as to the progress of their ongoing projects.   Avacta Group PLC – Alastair Smith, CEO Alastair Smith discussed the benefits on Affirmer technologies and updated their shareholders after their successful £10m fund-raise in August 2018.   Coro Energy PLC – Andrew Dennan, CFO Coro Energy’s CFO, Andy Dennan attended in the absence of James…read more >
Immupharma Plc Successful Placing To Raise £10 Million

Immupharma Plc Successful Placing To Raise £10 Million

RNS Number : 7232C  ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that, in response to institutional demand, it has completed a fundraise totalling £10 million (before expenses) via a placing of 6,944,445 new ordinary shares of 10p each in the Company (“Ordinary Shares”) at a price of 144p per share (the “Placing Shares”) with new and existing investors (the “Placing”). Key highlights: £10 million (before expenses) raised for the Company via the issue of Placing Shares: · Major new and existing institutional investors have participated in the Placing; and · ImmuPharma will apply these…read more >
Deltex Medical Group Plc Successful Placing, Subscription and Offer

Deltex Medical Group Plc Successful Placing, Subscription and Offer

Deltex Medical Group plc (“Deltex” or the “Company”)  Placing by way of an accelerated bookbuild and proposed Subscription to raise £1.75 million and Offer to Shareholders to raise up to £350,000  Deltex (AIM: DEMG), announces its intention to undertake an equity placement of £1,064,500 (the “Placing“). The Placing will be effected by way of an accelerated bookbuild, which will be launched immediately following this announcement at a minimum price of 1.25p. Certain other investors are proposing to invest £685,500 in the Company, by way of a subscription at the Issue Price (the “Subscription“). Arden Partners plc (“Arden“) and Turner Pope Investments (TPI)…read more >